Pulmonary Vascular Disease
📧 Sign up to get email alerts when something new happens for Pulmonary Vascular Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD) [NA]
A completed University of Zurich study compared exercise performance in pulmonary vascular disease patients when breathing ambient air versu…
-
CLINICAL_TRIALS trial_result · 2023-10-18Clinical Trial Update: Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI [Phase 2]
Phase 2 trial evaluating inhaled prostacyclin with hyperpolarized xenon MRI for response assessment in pulmonary vascular disease has comple…
-
CLINICAL_TRIALS trial_result · 2022-11-04Clinical Trial Update: A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease [Phase 2]
Phase 2 long-term study assessing macitentan for heart failure with preserved ejection fraction and pulmonary vascular disease. The trial wa…
-
CLINICAL_TRIALS trial_result · 2022-02-22Clinical Trial Update: Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging [Phase 2]
Phase 2 trial update on non-invasive diagnosis of pulmonary vascular disease using inhaled 129Xe MRI; results completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-05-05Clinical Trial Update: Evaluation of Dynamic Pulmonary Vascular Resistance in Patients With Closed Ventricular Septal Defect [NA]
A completed clinical trial from Universitaire Ziekenhuizen KU Leuven evaluated dynamic pulmonary vascular resistance in patients with closed…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-06-08Clinical Trial Update: EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection [Phase 3]
Phase 3 trial evaluating EZ-2053 for prophylaxis of acute pulmonary allograft rejection; the study is completed and results were posted.